Terumo cuts fiscal 2027 operating profit forecast 37.9% to 160 billion yen
Key Facts
Terumo cut its operating profit forecast for the fiscal year ending March 31, 2027, by 37.9% to 160,000 million yen, in a revision announced by the company on October 8, 2026, after it agreed with CSL Plasma to end their supply agreement following an agreed transition period. It also cut its forecast for net profit attributable to owners of the parent by 37.9% to 120,000 million yen, according to a Terumo statement. The company lowered its revenue forecast by 0.8% to 1,229,500 million yen. In contrast, it kept its adjusted operating profit forecast at 274,500 million yen. The figures put the agreement's termination at the center of the cut to the current fiscal year's forecasts.
The operating profit forecast was cut by 97,500 million yen from previous guidance of 257,500 million yen, while the estimate for net profit attributable to owners fell by 73,100 million yen from 193,100 million yen. Revenue estimates declined by 9,500 million yen from 1,239,000 million yen. The comparison provided by the company shows that the revision focused more on earnings than sales, as adjusted operating profit remained at its previous level of 274,500 million yen. Actual results for the fiscal year ended March 31, 2026, were revenue of 1,131,877 million yen, operating profit of 176,320 million yen and net profit attributable to owners of 135,914 million yen. Those prior results provide a measure of the scale of the new forecasts, but relate to a fiscal year that ended before the period covered by the revision.
Terumo estimated the total financial impact of ending the agreement at about $610 million for the fiscal year ending March 31, 2027, including about $450 million in non-cash impairment losses. The company said the remainder, estimated at about $160 million or 25.5 billion yen, is mainly related to expected losses during the transition period, as well as costs to terminate the agreement and restructure the business. Impairment losses therefore account for most of the stated impact, while the remainder includes expenses and losses related to ending and transitioning from the commercial relationship. Terumo said these amounts are preliminary estimates that may change depending on contractual negotiations, transition arrangements, asset valuations and other factors. The transition period remains part of the terminated agreement, according to the company's statement.
Terumo Blood and Cell Technologies, a wholly owned subsidiary of Terumo, began working with CSL Plasma in 2021 to supply source plasma collection devices to CSL Plasma centers in the United States. The parties mutually agreed to end the supply agreement, with agreed transition arrangements. In addition to the impact related to the agreement, Terumo said it expects a positive impact of about 2.0 billion yen on adjusted operating profit as future depreciation and amortization expenses decline after the impairment loss is recorded. It also expected expenses of about 2.0 billion yen related to the acquisition of Arsenal Medical, including research and development. The company kept its adjusted operating profit forecast for the fiscal year at 274,500 million yen despite these items cited in the statement.
Terumo shares, listed under the ticker 4543.T, closed at 2,516 yen in the November 11, 2026, session, according to EL7 data. The closing price came the day before the scheduled release of first-half results for the fiscal year ending in March 2027, not on the day Terumo announced its forecast revision in October. Terumo's investor relations calendar set November 12 as the date for the first-half results and also indicated that third-quarter results would be announced in early February. The investor relations website published the first-half results and accompanying presentation materials dated November 12, 2026. These subsequent reporting dates provide context for tracking the company's fiscal-year estimates.